Welcome to our dedicated page for Hangzhou Tigerme news (Ticker: HNGZY), a resource for investors and traders seeking the latest updates and insights on Hangzhou Tigerme stock.
The HANGZHOU TIGRMD UNSP/ADR (HNGZY) news page aggregates company communications and media coverage related to Hangzhou Tigermed Consulting Co., Ltd. (“Tigermed”), a Contract Research Organization that describes itself as a leading global provider of integrated research and development solutions for the biopharmaceutical and medical device industry. These updates give investors and observers insight into how Tigermed’s clinical, laboratory and global operations evolve over time.
News items commonly include financial results announcements, such as interim and full-year results. In these releases, Tigermed reports revenue trends, segment performance for clinical trial solutions and clinical-related and lab services, and information about backlog and new bookings. They also highlight business metrics like numbers of ongoing clinical trials, medical device and IVD projects, multi-regional clinical trials, and site management projects.
Another key category of coverage involves strategic expansion and acquisitions. Tigermed has announced the acquisition of Marti Farm, a European CRO focused on pharmacovigilance and clinical operations, and the acquisition of Micron, a Japan-based imaging CRO specializing in medical imaging and clinical trial services. It also reports acquisitions such as Medical Edge in Japan and preclinical and bioanalytical assets in Italy through Frontage Holdings, illustrating how the company extends its capabilities and regional presence.
News releases also describe technology and platform developments, including decentralized clinical trial (DCT) tools, remote monitoring systems, electronic source data repositories, and AI-enabled platforms like the YiYa AI Intelligent Translation Platform and the YiYa AI LLM platform. In addition, Tigermed communicates milestones such as the opening of its International Headquarters in Hong Kong, the construction of its global headquarters, new laboratories and offices, and recognitions related to ESG ratings and industry awards.
By following HNGZY news, readers can monitor Tigermed’s reported clinical project activity, geographic expansion, technology initiatives and corporate developments as disclosed in its own announcements and related media coverage.
Hangzhou Tigermed Consulting reported strong financial results for the first half of 2022, achieving a 74.8% year-over-year growth in total revenue to RMB 3,594.2 million. The adjusted net profit attributable to owners rose by 26.6% to RMB 876.5 million. The company’s revenue from Clinical Trial Solutions surged by 110.1%, while overseas revenue doubled, increasing by 102.3%. As of June 30, 2022, Tigermed was managing 607 ongoing drug projects, including 207 international ones, and it ranked as the largest clinical service provider in China with a 12.5% market share.
Hangzhou Tigermed Consulting Co., Ltd. reported impressive 2021 annual results, achieving a 63.3% year-over-year revenue growth of RMB 5,213.5 million. The company's adjusted net profit attributable to owners rose by 60.6% to RMB 1,585.3 million. Significant revenue increases were noted in Clinical Trial Solutions (up 97.1%) and overseas markets (up 91.1%). New bookings surged 74.2% YoY, totaling RMB 9,645.5 million. In 2021, Tigermed expanded globally with over 8,300 employees across 52 countries, continuing to innovate in clinical research.
Tigermed, a leading clinical research organization based in Hangzhou, China, has been awarded the Frost & Sullivan 2021 China Contract Research Organization Competitive Strategy Leadership Award. This recognition highlights Tigermed's dedication to high standards and comprehensive services in the biopharmaceutical and medical device sectors. With over 8,000 employees and operations spanning 46 countries, Tigermed is positioned to drive growth in China's clinical CRO market.
Hangzhou Tigermed Consulting Co. reported impressive interim results for the six months ended June 30, 2021. Total revenue surged by 41.6% to RMB 2,056.4 million, while net profit increased by 52.0% to RMB 1,594.2 million. Adjusted non-IFRS net profit rose 69.8% to RMB 692.1 million, reflecting robust growth across clinical trial and laboratory services. New bookings soared 150.8% to RMB 5,074.8 million, showcasing strong demand in both domestic and overseas markets.
Hangzhou Tigermed Consulting Co., Ltd. reported robust annual results for 2020, reflecting a 13.9% revenue growth to RMB 3,192.3 million. Key drivers included a 12.8% increase in Clinical Trial Solutions revenue and a 14.9% rise in Clinical-related Services. Net profit surged 108.3% year-over-year to RMB 2,030.6 million. The company also saw a 44.9% growth in its backlog, totaling RMB 7,260.3 million. Despite COVID-19 challenges, operations resumed, and expansions occurred in various regions. Overall, Tigermed's strategic growth initiatives position it well in the clinical research sector.
On February 25, 2021, the China National Medical Products Administration granted conditional marketing authorization for the Ad5-nCoV vaccine, developed collaboratively by CanSino Biologics and a research team led by Professor Wei Chen. Tigermed played a crucial role as a clinical contract research organization, managing a multicenter Phase III clinical study across several countries, including Pakistan and Mexico, involving over 40,000 subjects. The interim results indicate the vaccine's efficacy at preventing symptomatic COVID-19 is approximately 65.28%, with a 90.07% efficacy against severe disease.